Arrowhead Pharmaceuticals, Inc.

Ownership Transactions Reported by 15 Insiders

Symbol
ARWR on Nasdaq
Location
177 E Colorado Blvd, Suite 700, Pasadena, CA

Insiders trading volume in the past year

Arrowhead Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Christopher Anzalone Chief Executive Officer, Director $122M -$2.51M -2.02% Jan 31, 2024
Patrick O'Brien COO and General Counsel $17.4M -$1.14M -6.17% Jan 3, 2024
Kenneth Myszkowski Chief Financial Officer $14.1M -$1.98M -12.3% Mar 6, 2024
Javier San Chief Medical Officer $7.42M -$293K -3.8% Jan 4, 2024
James Hamilton Chief Discovery/Trans Medicine $5.74M -$1.79M -23.8% Apr 1, 2024
Douglas B. Given Director $4.85M -$111K -2.23% Jan 11, 2024
Michael Perry Director $4.29M Dec 15, 2023
James Hassard Chief Commercial Officer $3.95M Jun 22, 2021
Tracie Oliver Chief Commercial Officer $3.21M -$240K -6.95% Jul 2, 2024
Mauro Ferrari Director $2.27M -$120K -5.01% Jan 11, 2024
William D. Waddill Director $1.79M -$150K -7.72% Jan 11, 2024
Marianne De Backer Director $1.17M Jan 10, 2023
Hongbo Lu Director $912K +$145K +18.9% Sep 30, 2024
Adeoye Y. Olukotun Director $854K Dec 15, 2023
Victoria Vakiener Director $704K -$222K -24% May 2, 2024

Recent Insider Transactions by Companies or Individuals for Arrowhead Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.